Biotechnology & Life Sciences M&A Transactions

Fulcrum Therapeutics

Fulcrum Therapeutics and Slate Medicines merge, creating a new Nasdaq-listed biotech focused on migraine treatments, bolstered by $245 million in new funding.

LEO Pharma secures global rights to dersimelagon, a promising oral therapy for rare skin conditions EPP and XLP, in a deal valued up to $435 million.

Valerio Therapeutics advances its €30 million acquisition of Etherna Immunotherapies, securing regulatory clearance and targeting a late August deal signing.

Jasper Therapeutics

Jasper Therapeutics merges with Kira Pharmaceuticals, enhancing its immunology pipeline with three key assets and securing $132 million in financing for extended operational runway.

PTC Therapeutics secures ST-920 Fabry gene therapy from Sangamo Therapeutics for up to $211M, enhancing its rare disease treatment portfolio.

Danish firm Again integrates Geno's AI design platform with its biomanufacturing tech, boosting sustainable production of bio-based chemicals and materials.

Viome Life Sciences acquires Circulate Health, integrating plasma exchange technology to advance its mission in the rapidly growing longevity and healthspan sector.

Again integrates Genomatica's AI and bioprocess expertise to create a leading biomanufacturing platform, from discovery to scale.

Again's acquisition of Genomatica merges AI discovery with industrial scale-up, creating a leading biomanufacturing platform for sustainable products.